You are here: Industry Insights > Lilly

News List

Top Pharma & Biopharma Quarterly Results contractpharma
August 26, 2020
Pfizer: 2Q Revenues: $11.8 billion (-11%). 2Q Earnings: $3.4 billion (-32%). YTD Revenues: $23.8 billion (-10%). YTD Earnings: $6.8 billion (-24%)...
Financial Report, Lilly contractpharma
August 12, 2020
Trulicity revenues up 20% in the quarter, driven by increased demand.
Financial Report: Lilly contractpharma
April 24, 2020
Revenue up 15% in the quarter due to key growth products Trulicity, Taltz, Verzenio, Emgality, Basaglar, Jardiance, and Baqsimi.
Lilly to test Olumiant, LY3127804 against COVID-19 pharmatimes
April 14, 2020
Lilly has linked with health officials in the US to assess its rheumatoid arthritis drug Olumiant (baricitinib) in patients hospitalised with COVID-19.
Lilly, Indiana State Department of Health Partner to Accelerate COVID-19 Testing Using Lilly Research Laboratories PRNewswire
March 19, 2020
Eli Lilly and Company announced today its scientists are partnering with the Indiana State Department of Health (ISDH), with support from the Food and Drug Administration (FDA), to accelerate testing in Indiana for SARS-CoV-2, the virus that causes COVID-
Lilly to acquire Dermira for approximately $1.1bn pharmaceutical-technology
January 14, 2020
Eli Lilly and Company (Lilly) has signed a definitive agreement to acquire biopharmaceutical firm Dermira for approximately $1.1bn in cash. As agreed, Lilly will acquire all outstanding shares of Dermira for $18.75 per share.
Lilly Opens Phase 3 Clinical Trial in RET-Mutant Medullary Thyroid Cancer americanpharmaceuticalreview
January 02, 2020
Eli Lilly and Company announced the opening of the LIBRETTO-531 clinical trial for selpercatinib, also known as LOXO-292, for treatment-naïve RET-mutant medullary thyroid cancer (MTC) patients.
Jardiance phase 3 exercise ability studies in chronic heart failure fail to meet primary endpoint pharmaceutical-business-review
December 20, 2019
Jardiance, a type 2 diabetes drug developed by Boehringer Ingelheim and Eli Lilly and Company (Lilly), failed to meet the primary endpoint of two late-stage exercise ability trials in chronic heart failure.
CEO urges patients to get Lilly's help paying for insulin fiercepharma
December 20, 2019
After two senators criticized Eli Lilly over access to discounted insulin this week, CEO David Ricks called findings from their report “nonsense."
Boehringer Ingelheim, Lilly Provides Update on Jardiance Study americanpharmaceuticalreview
December 18, 2019
Boehringer Ingelheim and Eli Lilly and Company announced results from the EMPERIAL-Reduced and EMPERIAL-Preserved trials related to functional endpoints with Jardiance® (empagliflozin) ...

Previous page 1 2 3 4 5 6 7 8 9 10 ... 25 26 Next page